What is the NOAEL for 4-Androstene-3,17-dione?
4-Androstene-3,17-dione has 100 NOAEL studies in the database. The lowest reported value is 0.00414685502410049 uM. Source: NTP_ICE_endocrine.
NOAEL Data
Prop 65
REACH Registered
Cosmetic Ingredient
4-Androstene-3,17-dione
Also known as: Androstenedione, SKF 2170, Androst-4-ene-3 ,17-diona, Fecundin, NSC 9563 (+14 more)
CAS 63-05-8
4-Androstene-3,17-dione (CAS 63-05-8) is a chemical substance; key hazard signal: cancer. Key regulatory status: California Proposition 65, REACH registered, 14 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat, ECHA REACH, CA Prop 65.
Cross-Vertical Regulatory Divergence
4-Androstene-3,17-dione is prohibited in EU cosmetics but has active industrial GHS classifications (H302, H351, H360, H362).
SOURCE
Cross-vertical comparison
Cosmetics: ingredients.eu_status; Chemicals: ghs_classifications.signal_word/hazard_statement_code
SOURCE
noael studies public
NOAEL studies
100
SOURCE
chemical inventory jurisdictions
Regulatory lists
14
SOURCE
eu clp annex vi
GHS signal
Not classified
Chemical Identity
CAS, identifiers, formula, and alternate names for the matched substance record.
SOURCE
DSSTox identifiers
25 fields
Name
4-Androstene-3,17-dione
CAS Number
63-05-8
DTXSID
DTXSID8024523
Molecular Formula
C19H26O2
InChI Key
AEMFNILZOJDQLW-QAGGRKNESA-N
Monoisotopic Mass
286.19328
Synonyms
AndrostenedioneSKF 2170Androst-4-ene-3 ,17-dionaFecundinNSC 9563delta-4-Androsten-3,17-dionedelta-4-AndrostenedioneAndrotexEINECS 200-554-5delta(sup 4)-Androstene-3,17-dionedelta-(sup4)-Androsten-3,17-dioneUNII-409J2J96VR
California Proposition 65
California OEHHA listing status and toxicity category.
SOURCE
California OEHHA Proposition 65 List
1 records
| Chemical | Toxicity Type | Cancer | Developmental | Listed |
|---|---|---|---|---|
| - | cancer | Yes | No | - |
Functional Uses
Industrial and product-use categories associated with this substance.
SOURCE
EPA CPDat
2 records
Pharmaceutical
Regulatory Lists
Inventory, screening, and regulatory list matches from public chemical databases.
SOURCE
EPA CPDat
14 records
| List | Keyword | Source |
|---|---|---|
| detected; MN Chemical Screening; surface_water | Minnesota Pollution Control Agency | State of Minnesota |
| detected; drinking_water; MN Chemical Screening | EPA | State of Minnesota |
| detected; drinking_water; MN Chemical Screening | EPA | State of Minnesota |
| detected; drinking_water; MN Chemical Screening | EPA | State of Minnesota |
| detected; drinking_water; MN Chemical Screening | EPA | State of Minnesota |
| OEHHA Proposition 65 (3/2019) | STATE OF CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY | OEHHA Proposition 65 List |
| detected; MN Chemical Screening; surface_water | Minnesota Pollution Control Agency | State of Minnesota |
| detected; MN Chemical Screening; surface_water | Minnesota Pollution Control Agency | State of Minnesota |
| detected; MN Chemical Screening; surface_water | Minnesota Pollution Control Agency | State of Minnesota |
| Canada; pharmaceutical | DrugBank | DrugBank |
| Canada; pharmaceutical | DrugBank | DrugBank |
| OEHHA Proposition 65 (1/2023) | California Office of Environmental Health Hazard Assessment | OEHHA Proposition 65 List |
| pharmaceutical; prohibited | World Anti-Doping Agency | World Anti-Doping Agency |
| pharmaceutical; prohibited | World Anti-Doping Agency | World Anti-Doping Agency |
NOAEL Studies
Toxicology endpoints rendered from public NOAEL study rows.
SOURCE
NOAEL studies
Showing 50 of 100 studies
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 0.0308758414104603 | uM | AC50 | - | - | NTP_ICE_endocrine |
| 0.325428797 | uM | AC50 | - | - | NTP_ICE_endocrine |
| 0.0072 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 0.27 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 0.3 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 3.981 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 4.18 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 8.92 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 10.1 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 10.8 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 15 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 18.87 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 20 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 24.3 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 35 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 37.9 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 41.1 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 41.3 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 45 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 50 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 55.5 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 58 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 90 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 91.2 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 99 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 100 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 130 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 140 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 203 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 218.8 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 281.8 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 312.5 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 500 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 620 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 1000 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 1020 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 1280 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 1800 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 1928 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 3400 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 3607 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 4900 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 7200 | nM | AC50/EC50/IC50 | - | - | NTP_ICE_endocrine |
| 0.00414685502410049 | uM | ACC | - | - | NTP_ICE_endocrine |
| 0.049702621 | uM | ACC | - | - | NTP_ICE_endocrine |
| ABcancer | listing type | California Proposition 65 listing | - | - | California Proposition 65 |
| ABcancer | listing type | California Proposition 65 listing | - | - | California Proposition 65 |
| ABcancer | listing type | California Proposition 65 listing | - | - | California Proposition 65 |
| 25.92 | uL/min/10^6 cells | Clint | - | Human | NTP_ICE_adme_parameters |
| =0.176 | mg/m3 | DNEL systemic | inhalation | Human | ToxValDB_GESTIS_DNEL |
Showing 50 of 100 studies
REACH Registration
Registration status from the ECHA REACH registered substances database.
SOURCE
ECHA (EU)
1 records
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | Androst-4-ene-3,17-dione | 200-554-5 | ECHA overview → |
Cosmetic Safety Profile
Same-CAS cosmetic ingredient record for cross-vertical context.
SOURCE
CosIng / Ingredients DB
EU Status
prohibited
Max
-
Category
Vitamins
Pharmaceutical Data
Same-CAS pharmaceutical records from drug and bioactivity sources.
SOURCE
EMBL-EBI ChEMBL
ANDROSTENEDIONE
ChEMBL Phase
-1
Adverse Events
0
Bioactivity
12
Food Safety Data
Same-CAS food additive, ADI, and GRAS records where available.
SOURCE
EFSA / FDA GRAS
1 records
1 food-safety record found.
View full food safety profile →Frequently Asked Questions
What regulatory lists include 4-Androstene-3,17-dione?
4-Androstene-3,17-dione appears on 6 regulatory/inventory lists including detected; MN Chemical Screening; surface_water, detected; drinking_water; MN Chemical Screening, OEHHA Proposition 65 (3/2019), and 3 more. Source: EPA CPDat.
Is 4-Androstene-3,17-dione on the California Proposition 65 list?
Yes, 4-Androstene-3,17-dione is listed under California Proposition 65 for cancer. Source: California OEHHA Proposition 65.
Is 4-Androstene-3,17-dione used in cosmetics?
Yes, 4-Androstene-3,17-dione is also indexed as a cosmetic ingredient under the name Androstenedione. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Where does the safety data for 4-Androstene-3,17-dione come from?
Safety data is sourced from EPA ToxValDB, EPA CPDat, EPA DSSTox, ECHA REACH, California Proposition 65, CosIng / Ingredients DB, ChEMBL / DailyMed, EFSA / FDA GRAS. All data traces to primary regulatory sources and is updated from official government databases.
Does 4-Androstene-3,17-dione have different safety status in cosmetics vs industrial chemicals?
4-Androstene-3,17-dione is prohibited in EU cosmetics but has active industrial GHS classifications (H302, H351, H360, H362).
Is 4-Androstene-3,17-dione used outside industrial chemicals?
4-Androstene-3,17-dione also appears in cosmetics, pharmaceutical, food safety databases.